TRADES
Latest Trades
104
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 28 Sep 2021 Sell NVS NOVARTIS AG 320,220 0.3484
ARKG 27 Sep 2021 Sell NVS NOVARTIS AG 107,020 0.1152
ARKG 23 Sep 2021 Sell NVS NOVARTIS AG 157,464 0.1674
ARKG 22 Sep 2021 Sell NVS NOVARTIS AG 241,747 0.2533
ARKG 21 Sep 2021 Sell NVS NOVARTIS AG 94,000 0.0990
ARKG 20 Sep 2021 Sell NVS NOVARTIS AG 37,238 0.0373
ARKG 16 Sep 2021 Sell NVS NOVARTIS AG 57,455 0.0610
ARKG 10 Sep 2021 Sell NVS NOVARTIS AG 59,691 0.0600
ARKG 9 Sep 2021 Sell NVS NOVARTIS AG 229,072 0.2400
ARKG 8 Sep 2021 Sell NVS NOVARTIS AG 193,937 0.2000
ARKG 1 Sep 2021 Sell NVS NOVARTIS AG 32,322 0.0352
ARKG 31 Aug 2021 Sell NVS NOVARTIS AG 142,994 0.1572
ARKG 18 Aug 2021 Sell NVS NOVARTIS AG 52,621 0.0616
ARKG 17 Aug 2021 Sell NVS NOVARTIS AG 30,729 0.0357
ARKG 12 Aug 2021 Sell NVS NOVARTIS AG 92,693 0.1011
ARKG 11 Aug 2021 Sell NVS NOVARTIS AG 86,320 0.0927
ARKG 10 Aug 2021 Sell NVS NOVARTIS AG 53,188 0.0551
ARKG 9 Aug 2021 Sell NVS NOVARTIS AG 100,687 0.1045
ARKG 4 Aug 2021 Sell NVS NOVARTIS AG 133,173 0.1416
ARKG 3 Aug 2021 Sell NVS NOVARTIS AG 143,100 0.1538
ARKG 2 Aug 2021 Sell NVS NOVARTIS AG 76,404 0.0821
ARKG 27 Jul 2021 Sell NVS NOVARTIS AG 47,098 0.0498
ARKG 26 Jul 2021 Sell NVS NOVARTIS AG 60,066 0.0619
ARKG 23 Jul 2021 Sell NVS NOVARTIS AG 242,578 0.2505
ARKK 23 Jul 2021 Sell NVS NOVARTIS AG 216 0.0001
ARKK 22 Jul 2021 Sell NVS NOVARTIS AG 2,800 0.0011
ARKK 21 Jul 2021 Sell NVS NOVARTIS AG 10,000 0.0040
ARKK 20 Jul 2021 Sell NVS NOVARTIS AG 40,000 0.0167
ARKK 19 Jul 2021 Sell NVS NOVARTIS AG 81,600 0.0341
ARKK 16 Jul 2021 Sell NVS NOVARTIS AG 256,150 0.1077
ARKG 15 Jul 2021 Sell NVS NOVARTIS AG 98,887 0.1041
ARKK 15 Jul 2021 Sell NVS NOVARTIS AG 183,740 0.0750
ARKG 14 Jul 2021 Sell NVS NOVARTIS AG 85,913 0.0880
ARKK 13 Jul 2021 Sell NVS NOVARTIS AG 74,815 0.0294
ARKK 12 Jul 2021 Sell NVS NOVARTIS AG 120,883 0.0474
ARKK 7 Jul 2021 Sell NVS NOVARTIS AG 131,960 0.0499
ARKG 17 Jun 2021 Sell NVS NOVARTIS AG 349,532 0.3763
ARKG 16 Jun 2021 Sell NVS NOVARTIS AG 128,903 0.1391
ARKG 15 Jun 2021 Sell NVS NOVARTIS AG 139,576 0.1461
ARKK 14 Jun 2021 Sell NVS NOVARTIS AG 9,409 0.0040
ARKK 11 Jun 2021 Sell NVS NOVARTIS AG 124,596 0.0530
ARKK 10 Jun 2021 Sell NVS NOVARTIS AG 100,388 0.0434
ARKG 2 Jun 2021 Sell NVS NOVARTIS AG 41,594 0.0449
ARKG 26 May 2021 Sell NVS NOVARTIS AG 166,980 0.1814
ARKK 24 May 2021 Sell NVS NOVARTIS AG 44,973 0.0193
ARKK 20 May 2021 Sell NVS NOVARTIS AG 110,405 0.0484
ARKK 19 May 2021 Sell NVS NOVARTIS AG 108,426 0.0485
ARKK 18 May 2021 Sell NVS NOVARTIS AG 152,433 0.0683
ARKK 17 May 2021 Sell NVS NOVARTIS AG 9,910 0.0045
ARKK 13 May 2021 Sell NVS NOVARTIS AG 236,796 0.1112
ARKK 12 May 2021 Sell NVS NOVARTIS AG 179,700 0.0809
ARKK 11 May 2021 Sell NVS NOVARTIS AG 21,128 0.0091
ARKK 7 May 2021 Sell NVS NOVARTIS AG 205,923 0.0877
ARKK 6 May 2021 Sell NVS NOVARTIS AG 234,800 0.1002
ARKG 3 May 2021 Sell NVS NOVARTIS AG 59,216 0.0546
ARKG 29 Apr 2021 Sell NVS NOVARTIS AG 112,985 0.1002
ARKK 28 Apr 2021 Sell NVS NOVARTIS AG 148,180 0.0525
ARKG 21 Apr 2021 Sell NVS NOVARTIS AG 11,038 0.0102
ARKG 20 Apr 2021 Sell NVS NOVARTIS AG 57,600 0.0541
ARKG 19 Apr 2021 Sell NVS NOVARTIS AG 27,353 0.0258
ARKG 30 Mar 2021 Sell NVS NOVARTIS AG 100,127 0.0967
ARKG 29 Mar 2021 Sell NVS NOVARTIS AG 92,709 0.0913
ARKK 25 Mar 2021 Sell NVS NOVARTIS AG 71,063 0.0287
ARKK 4 Mar 2021 Sell NVS NOVARTIS AG 131,888 0.0506
ARKK 1 Mar 2021 Sell NVS NOVARTIS AG 58,657 0.0207
ARKK 26 Feb 2021 Sell NVS NOVARTIS AG 223,902 0.0822
ARKK 25 Feb 2021 Sell NVS NOVARTIS AG 14,692 0.0054
ARKK 12 Feb 2021 Buy NVS NOVARTIS AG 155,469 0.0512
ARKK 11 Feb 2021 Buy NVS NOVARTIS AG 194,772 0.0649
ARKG 10 Feb 2021 Buy NVS NOVARTIS AG 87,684 0.0639
ARKK 10 Feb 2021 Buy NVS NOVARTIS AG 90,902 0.0307
ARKG 9 Feb 2021 Buy NVS NOVARTIS AG 426,773 0.3095
ARKG 8 Feb 2021 Buy NVS NOVARTIS AG 47,803 0.0351
ARKK 8 Feb 2021 Buy NVS NOVARTIS AG 15,467 0.0054
ARKK 5 Feb 2021 Buy NVS NOVARTIS AG 282,125 0.0999
ARKK 4 Feb 2021 Buy NVS NOVARTIS AG 247,057 0.0883
ARKG 3 Feb 2021 Buy NVS NOVARTIS AG 299,907 0.2332
ARKG 2 Feb 2021 Buy NVS NOVARTIS AG 30,705 0.0243
ARKK 29 Jan 2021 Buy NVS NOVARTIS AG 92,187 0.0400
ARKK 28 Jan 2021 Buy NVS NOVARTIS AG 150,052 0.0600
ARKK 26 Jan 2021 Buy NVS NOVARTIS AG 364,291 0.1473
ARKG 21 Jan 2021 Buy NVS NOVARTIS AG 77,165 0.0668
ARKG 20 Jan 2021 Buy NVS NOVARTIS AG 195,595 0.1686
ARKG 19 Jan 2021 Buy NVS NOVARTIS AG 62,491 0.0600
ARKG 15 Jan 2021 Buy NVS NOVARTIS AG 104,619 0.0982
ARKG 14 Jan 2021 Buy NVS NOVARTIS AG 166,098 0.1500
ARKK 13 Jan 2021 Buy NVS NOVARTIS AG 460,412 0.2000
ARKK 12 Jan 2021 Buy NVS NOVARTIS AG 199,208 0.0869
ARKK 11 Jan 2021 Buy NVS NOVARTIS AG 213,392 0.0967
ARKK 8 Jan 2021 Buy NVS NOVARTIS AG 224,573 0.1015
ARKK 7 Jan 2021 Buy NVS NOVARTIS AG 50,104 0.0233
ARKG 4 Jan 2021 Buy NVS NOVARTIS AG 145,574 0.1797
ARKG 30 Dec 2020 Buy NVS NOVARTIS AG-SPONSORED ADR 14,273 0.0200
ARKG 29 Dec 2020 Buy NVS NOVARTIS AG 127,579 0.1602
ARKG 28 Dec 2020 Buy NVS NOVARTIS AG 274,836 0.3254
ARKG 24 Dec 2020 Buy NVS NOVARTIS AG 98,758 0.1127
ARKG 23 Dec 2020 Buy NVS NOVARTIS AG 90,543 0.1050
ARKG 17 Dec 2020 Buy NVS NOVARTIS AG 196,970 0.2987
ARKG 15 Dec 2020 Buy NVS NOVARTIS AG 158,309 0.2423
ARKG 8 Dec 2020 Buy NVS NOVARTIS AG 166,885 0.2897
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.